Latent tuberculosis infection

Seminars in Respiratory and Critical Care Medicine

Volumn 25, Issue 3, 2004, Pages 317-336

  Nuermberger, Eric ^a   Bishai, William R ^a   Grosset, Jacques H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dual TB + HIV infection; Latency; Preventive therapy; Tuberculosis

Indexed keywords

BCG VACCINE; CLARITHROMYCIN; ETHAMBUTOL; ISONIAZID; METHADONE; MOXIFLOXACIN; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; PYRAZINAMIDE; PYRIDOXINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAMYCIN DERIVATIVE; RIFAPENTINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL TRANSMISSION; BILIRUBIN BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG DESIGN; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HEPATITIS; HIGH RISK POPULATION; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LATENT TUBERCULOSIS INFECTION; LIVER TOXICITY; MOLECULAR GENETICS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RADIOLOGY; RASH; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; TUBERCULIN TEST; TUBERCULOSIS; UVEITIS; VOMITING;

EID: 3042733415     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-829504     Document Type: Review

References (149)

1. Tufariello JM, Chan J, Flynn JL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 2003;3:578-590
2. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009-1021
3. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 1999;282:677-686
4. Styblo K, Meijer J, Sutherland I. The transmission of tubercle bacilli: its trend in a human population. Bull World Health Organ 1969;41:137-178
5. Enarson DA, Rouillon A. The epidemiological basis of tuberculosis control. In: Davis PDO, ed. Clinical Tuberculosis. London: Chapman & Hall; 1994:19-32
6. Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res 1976;19:1-63
7. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-550
8. Manabe YC, Bishai WR. Latent Mycobacterium tuberculosis-persistence, patience, and winning by waiting. Nat Med 2000;6:1327-1329
9. Russell DG. Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol 2001;2:569-577
10. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 2002;43:717-731
11. Wayne LG, Sohaskey CD. Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol 2001;55: 139-163
12. Yuan Y, Crane DD, Barry CE. 3. Stationary phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial alpha-crystallin homolog. J Bacteriol 1996;178:4484-4492
13. Boon C, Li R, Qi R, Dick T. Proteins of Mycobacterium bovis BCG induced in the Wayne dormancy model. J Bacteriol 2001;183:2672-2676
14. Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrell MI, Schoolnik GK. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha-crystallin. Proc Natl Acad Sci USA 2001;98:7534-7539
15. Cunningham AF, Spreadbury CL. Mycobacterial stationary phase induced by low oxygen tension: cell wall thickening and localization of the 16-kilodalton alpha-crystallin homolog. J Bacteriol 1998;180:801-808
16. Yuan Y, Crane DD, Simpson RM, et al. The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc Natl Acad Sci USA 1998;95:9578-9583
17. DeMaio J, Zhang Y, Ko C, Young DB, Bishai WR. A stationary-phase stress-response sigma factor from Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1996;93:2790-2794
18. Chen P, Ruiz RE, Li Q, Silver RF, Bishai WR. Construction and characterization of a Mycobacterium tuberculosis mutant lacking the alternate sigma factor gene, sigF. Infect Immun 2000;68:5575-5580
19. Geiman DE, Kaushal D, Ko C, et al. Attenuation of late-stage disease in mice infected by the Mycobacterium tuberculosis mutant lacking the SigF alternate sigma factor and identification of SigF-dependent genes by microarray analysis. Infect Immun 2004, In press
20. Wayne LG. Dynamics of submerged growth of Mycobacterium tuberculosis under aerobic and microaerophilic conditions. Am Rev Respir Dis 1976;114:807-811
21. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996;64: 2062-2069
22. Wayne LG, Lin KY. Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect Immun 1982;37:1042-1049
23. Boon C, Dick T. Mycobacterium bovis BCG response regulator essential for hypoxic dormancy. J Bacteriol 2002;184: 6760-6767
24. Park HD, Guinn KM, Harrell MI, et al. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Myrobacterium tuberculosis. Mol Microbiol 2003;48:833-843
25. Florczyk MA, McCue LA, Purkayastha A, Currenti E, Wolin MJ, McDonough KA. A family of acr-coregulated Mycobacterium tuberculosis genes shares a common DNA motif and requires Rv3133c (dosR or devR) for expression. Infect Immun 2003;71:5332-5343
26. Voskuil MI, Schnapppinger D, Visconti KC, et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 2003;198:705-713
27. Shi L, Jung YJ, Tyagi S, Gennaro ML, North RJ. Expression of Th1-mediated immunity in mouse lungs induces a Mycobacterium tuberculosis transcription pattern characteristic of nonreplicating persistence. Proc Natl Acad Sci USA 2003; 100:241-246
28. Hingley-Wilson SM, Sambandamurthy VK, Jacobs WR Jr. Survival perspectives from the world's most successful pathogen, Mycobacterium tuberculosis. Nat Immunol 2003;4: 949-955
29. McKinney JD, Honer zu Bentrup K, Munoz-Elias EJ, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000;406:735-8
30. Dahl JL, Kraus CN, Boshoff HI, et al. The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci USA 2003;100:10026-10031
31. Johansen KA, Gill RE, Vasil ML. Biochemical and molecular analysis of phospholipase C and phospholipase D activity in mycobacteria. Infect Immun 1996;64:3259-3266
32. Ando M, Yoshimatsu T, Ko C, Converse PJ, Bishai WR. Deletion of Mycobacterium tuberculosis sigma factor E results in delayed time to death with bacterial persistence in lungs of aerosol-infected mice. Infect Immun 2003, In press
33. Kaushal D, Schroeder BG, Tyagi S, et al. Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative sigma factor, SigH. Proc Natl Acad Sci USA 2002;99:8330-8335
34. Sun R, Converse PJ, Ko C, Tyagi S, Morrison NE, Bishai WR. Mycobacterium tuberculosis sigC is an ECF sigma factor required for lethality in mice and for the conditional expression of a defined set of genes. Mol Microbiol 2004; 52:25-38
35. Steyn AJ, Collins DM, Hondalus MK, Jacobs WR Jr, Kawakami RP, Bloom BR. Mycobacterium tuberculosis WhiB3 interacts with RpoV to affect host survival but is dispensable for in vivo growth. Proc Natl Acad Sci USA 2002;99:3147-3152
36. Lewis KN, Liao R, Guinn KM, et al. Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guerin attenuation. J Infect Dis 2003;187:117-123
37. Boshoff HIM, Reed MB, Barry CE III, Mizrahi V. DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell 2003; 113:183-193
38. Loudon RG, Williamson J, Johnson JM. An analysis of 3,485 tuberculosis contacts in the city of Edinburgh during 1954-1955. Am Rev Tuberc 1958;77:623-643
39. Nardell EA, Piessens WF. Transmission of tuberculosis. In: Reichman LB, Hershfield ES, eds. Tuberculosis: A Comprehensive International Approach. 2nd ed. New York: Marcel Dekker; 2000:215-240
40. Koch R. Die Atiologie der Tuberkulose. Berl Klin Wochenschr 1882;19:221-230
41. Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999;353:444-449
42. Loudon RG, Bumgarner LR, Lacy J, Coffman GK. Aerial transmission of mycobacteria. Am Rev Respir Dis 1969;100: 165-171
43. Wells W. On airborne infection, II: Droplets and droplet nuclei. Am J Hyg 1934;20:611-618
44. Shaw JB, Wynn-Williams N. Infectivity of pulmonary tuberculosis in relation to sputum status. Am Rev Tuberc 1954;69:724-732
45. Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. Bull Int Union Tuberc 1975; 50:90-106
46. van Geuns HA, Meijer J, Styblo K. Results of contact examination in Rotterdam, 1967-1969. Bull Int Union Tuberc 1975;50:107-121
47. Comstock GW. Epidemiology of tuberculosis. In: Reichman LB, Hershfield ES, eds. Tuberculosis: A Comprehensive International Approach. 2nd ed. New York: Marcel Dekker; 2000:129-156
48. Veen J. Microepidemics of tuberculosis: the stone-in-the-pond principle. Tuberc Lung Dis 1992;73:73-76
49. Houk VN, Baker JH, Sorensen K, Kent DC. The epidemiology of tuberculosis infection in a closed environment. Arch Environ Health 1968;16:26-35
50. Dickinson JM, Lefford MJ, Lloyd J, Mitchison DA. The virulence in the guinea-pig of tubercle bacilli from patients with pulmonary tuberculosis in Hong Kong. Tubercle 1963; 44:446-451
51. Middlebrook G, Cohn ML. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Science 1953;118:297-299
52. Pym AS, Saint-Joanis B, Cole ST. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 2002;70:4955-4960
53. Narain R, Naganna K, Murthy SS. Incidence of pulmonary tuberculosis. Am Rev Respir Dis 1973;107:992-1001
54. Barnes PF, Cave MD. Molecular epidemiology of tuberculosis. N Engl J Med 2003;349:1149-1156
55. O'Grady F, Riley RL. Experimental airborne tuberculosis. Adv Tuberc Res 1963;12:150-190
56. Valway SE, Sanchez MP, Shinnick TF, et al. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N Engl J Med 1998;338:633-639
57. Sutherland I. The ten-year incidence of clinical tuberculosis following "conversion" in 2550 individuals aged 14 to 19 years. The Hague: KNCV; 1968. TSTRU Progress Report
58. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 1969;17:28-106
59. Chiba Y, Kurihara T. Development of pulmonary tuberculosis with special reference to the time interval after tuberculin conversion. Bull Int Union Tuberc 1979;54: 263-264
60. Styblo K, Sutherland I. Epidemiology of tuberculosis in the child. Bull Int Union Tuberc 1982;57:134-141
61. Canetti G. The Tubercle Bacillus in the Pulmonary Lesions Of Man. New York: Springer; 1955
62. Rieder HL, Cauthen GM, Comstock GW, Snider DE Jr. Epidemiology of tuberculosis in the United States. Epidemiol Rev 1989;11:79-98
63. Hopewell PC, Chaisson RE. Tuberculosis and human immunodeficiency virus infection. In: Reichman LB, Hershfield ES, eds. Tuberculosis: A Comprehensive International Approach. 2nd ed. New York: Marcel Dekker; 2000:525-552
64. Cohn DL, El-Sadr W. Treatment of latent tuberculosis infection. In: Reichman LB and Hershfield ES, eds. Tuberculosis: A Comprehensive International Approach. 2nd ed. New York: Marcel Dekker; 2000:471-502
65. Bucher HC, Griffith LE, Guyatt GH, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999;13:501-507
66. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000;14:1985-1991
67. Centers for Disease Control and Prevention. Tuberculosis outbreak among persons in a residential facility for HIV-infected persons-San Francisco. MMWR Morb Mortal Wkly Rep 1991;40:649-652
68. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992;326:231-235
69. Dooley SW, Villarino ME, Lawrence M, et al. Nosocomial transmission of tuberculosis in a hospital unit for HIV-infected patients. JAMA 1992;267:2632-2634
70. Di Perri G, Cruciani M, Danzi MC, et al. Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet 1989;2:1502-1504
71. American Thoracic Society. Treatment of tuberculosis and other mycobacterial diseases. Am Rev Respir Dis 1983;127: 790-796
72. Jones JL, Hanson DL, Dworkin MS, DeCock KM. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. Int J Tuberc Lung Dis 2000;4:1026-1031
73. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 1992;268: 504-509
74. Centers for Disease Control and Prevention/American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2000;49:1-51
75. van Soolingen D, Borgdorff MW, de Haas PE, et al. Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997. J Infect Dis 1999;180:726-736
76. Burgos M, DeRiemer K, Small PM, Hopewell PC, Daley CL. Relative fitness of drug-resistant and drug-susceptible strains of Mycobacterium tuberculosis in San Francisco. Am J Respir Crit Care Med 2003;165(suppl 8):A18
77. Garcia-Garcia ML, Ponce DL, Jimenez-Corona ME, et al. Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico. Arch Intern Med 2000;160: 630-636
78. Godfrey-Faussett P, Sonnenberg P, Shearer SC, et al. Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet 2000;356:1066-1071
79. Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996;276:1229-1235
80. Kruuner A, Hoffner SE, Sillastu H, et al. Spread of drug-resistant pulmonary tuberculosis in Estonia. J Clin Microbiol 2001;39:3339-3345
81. Horwitz O, Comstock GW. What is a case of tuberculosis? The tuberculosis case spectrum in eight countries evaluated from 1235 case histories and roentgenograms. Int J Epidemiol 1973;2:145-152
82. Alland D, Kalkut GE, Moss AR, et al. Transmission of tuberculosis in New York City: an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994;330:1710-1716
83. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med 1994;330:1703-1709
84. Ferebee SH, Palmer CE. Prevention of experimental tuberculosis with isoniazid. Am Rev Tuberc 1956;73:1-18
85. Ferebee SH, Hopwood L, Palmer CE. Studies on prevention of experimental tuberculosis with isoniazid, II: Effects of different dosage regimens. Am Rev Tuberc 1956;74:917-939
86. Runyon EH. Preventive treatment in tuberculosis: a statement by the committee on therapy, American Thoracic Society. Am Rev Respir Dis 1965;91:297-298
87. International Union Against Tuberculosis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982;60:555-564
88. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis 1979;119:827-830
89. Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997;337:315-320
90. Hawken MP, Meme HK, Elliott LC, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 1997;11:875-882
91. Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998;12:2447-2457
92. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268-272
93. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997;337:801-808
94. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001;15:2137-2147
95. Quigley MA, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001;15:215-222
96. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999;3:847-850
97. Ferebee SH, Mount FW. Antituberculosis chemoprophylaxis with isoniazid. Am Rev Respir Dis 1963;87:453-454
98. Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis: report of an outbreak. Am Rev Respir Dis 1972;106:357-365
99. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978;117:991-1001
100. American Thoracic Society. Preventive therapy of tuberculous infection. Am Rev Respir Dis 1974;110:371-374
101. Mehta JB, Dutt AK, Harvill L, Henry W. Isoniazid preventive therapy for tuberculosis: are we losing our enthusiasm? Chest 1988;94:138-141
102. Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 1976;84:181-192
103. Scharer L, Smith JP. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 1969;71:1113-1120
104. Moulding TS, Redeker AG, Kanel GC. Twenty isoniazid-associated deaths in one state. Am Rev Respir Dis 1989; 140:700-705
105. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281: 1014-1018
106. Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997;127:1051-1061
107. Snider DE Jr, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992;145:494-497
108. Oestreicher R, Dressler SH, Middlebrook G. Peripheral neuritis in tuberculous patients treated with isoniazid. Am Rev Tuberc 1954;70:504-508
109. Snider DE. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980;61:191-196
110. Gourevitch MN, Alcabes P, Wasserman WC, Arno PS. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis. Int J Tuberc Lung Dis 1998;2:531-540
111. Hong Kong Chest Service/Tuberculosis Research Centre MBMRC. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992;145: 36-41
112. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989;140:1189-1193
113. Grosset J, Truffot-Pernot C, Lacroix C, Ji B. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 1992;36:548-551
114. Fox W. Drug combinations and the bioavailability of rifampicin. Tubercle 1990;71:241-245
115. Dhillon J, Dickinson JM, Sole K, Mitchison DA. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother 1996;40:552-555
116. Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA 2000;283:1445-1450
117. Halsey NA, Coberly JS, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998;351:786-792
118. Ormerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child 1998;78:169-171
119. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53:536-548
120. Polesky A, Farber HW, Gottlieb DJ, et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 1996;154:1473-1477
121. Villarino ME, Ridzon R, Weismuller PC, et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med 1997;155: 1735-1738
122. Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis 1983;5(suppl 3):S440-S450
123. Campagna M, Calix A, Hauser G. Observations on the combined use of pyrazinamide (Aldinamide) and isoniazid in the treatment of pulmonary tuberculosis; a clinical study. Am Rev Tuberc 1954;69:334-350
124. McDermott W, Ormond L, Muschenheim C, Deuschle K, McCune RM Jr, Tompsett R. Pyrazinamide-isoniazid in tuberculosis. Am Rev Tuberc 1954;69:319-333
125. Centers for Disease Control and Prevention. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 1992;41:61-71
126. Geiter LJ. Preventive therapy of tuberculosis. In: Gangadharam PRJ, Jenkins PA, eds. Mycobacteria, Vol 2: Chemotherapy. New York: Chapman & Hall; 1998:297-312
127. Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52: 735-739
128. Combs DL, O'Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990;112:397-406
129. Ji B, Truffot-Pernot C, Lacroix C, et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993;148:1541-1546
130. Chapuis L, Ji B, Truffot-Pernot C, O'Brien RJ, Raviglione MC, Grosset JH. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Crit Care Med 1994;150:1355-1362
131. Jabes D, Della BC, Rossi R, Olliaro P. Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis. Antimicrob Agents Chemother 1994;38:2346-2350
132. Miyazaki E, Chaisson RE, Bishai WR. Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis. Antimicrob Agents Chemother 1999;43:2126-2130
133. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999;353:1843-1847
134. Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:653-657
135. Lounis N, Bentoucha A, Truffot-Pernot C, et al. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001;45:3482-3486
136. Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2003;47:3117-3122
137. Perlman DC, El Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. Clin Infect Dis 1997;25:242-246
138. Snider DE Jr, Caras GJ, Koplan JP. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy. JAMA 1986;255:1579-1583
139. Khan K, Muennig P, Behta M, Zivin JG. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002;347:1850-1859
140. McGregor MM, Olliaro P, Wolmarans L, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996;154:1462-1467
141. Franks AL, Binkin NJ, Snider DE Jr, Rokaw WM, Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep 1989;104:151-155
142. Scheinhorn DJ, Angelillo VA. Antituberculous therapy in pregnancy: risks to the fetus. West J Med 1977;127: 195-198
143. Snider DE Jr, Powell KE. Should women taking anti-tuberculosis drugs breast-feed? Arch Intern Med 1984;144: 589-590
144. Nolan CM, Elarth AM. Tuberculosis in a cohort of Southeast Asian refugees: a five-year surveillance study. Am Rev Respir Dis 1988;137:805-809
145. Livengood JR, Sigler TG, Foster LR, Bobst JG, Snider DE Jr. Isoniazid-resistant tuberculosis: a community outbreak and report of a rifampin prophylaxis failure. JAMA 1985; 253:2847-2849
146. Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, Onorato IM. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis 1997;24:1264-1265
147. Horn DL, Hewlett D Jr, Alfalla C, Peterson S, Opal SM. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med 1994;330:1241
148. Lou HX, Shullo MA, McKaveney TP. Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population. Pharmacotherapy 2002;22:701-704
149. Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ 2002;167:131-136